What is the efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients?
The ODYSSEY ALTERNATIVE randomized trial reported on the efficacy and safety of alirocumab compared to ezetimibe in statin-intolerant patients. The trial found that alirocumab was more effective than ezetimibe at reducing low-density lipoprotein (LDL) cholesterol levels, with a mean reduction of 58.2% in the alirocumab group compared to 24.4% in the ezetimibe group. Additionally, alirocumab was found to be well-tolerated, with similar rates of adverse events between the two groups.